Shire (Dublin, Ireland) has entered into a definitive agreement to sell its oncology business to Servier (Neuilly-sur-Seine, France) for $2.4 billion.
Under the terms of the agreement, Servier has agreed to acquire Shire’s oncology business for a total consideration of $2.4 billion, in cash, upon completion. In 2017, the oncology business generated revenues of $262 million. The transaction covers the transfer of Shire's in-market products Oncaspar and ex-U.S. rights to Onivyde. The portfolio also includes Calaspargase Pegol (Cal-PEG), which is under FDA review for the treatment of ALL, and early stage immuno-oncology pipeline collaborations.
Shire CEO, Flemming Ornskov, commented: “While the oncology business has delivered high growth and profitability, we have concluded that it is not core to Shire’s longer-term strategy.We will continue to evaluate our portfolio for opportunities to unlock further value and sharpen our focus on rare disease leadership with selective disposals of non-strategic assets.
Olivier Laureau, Servier Group President, said: “The acquisition of Shire's oncology franchise enables Servier to meet its strategic ambitions to become a global key player in oncology. As an essential step in the evolution of the Group, this acquisition allows us to establish a direct commercial presence in the United States, the world's leading pharmaceuticals market, and to strengthen our portfolio of marketed products in the territories where Servier is already present."
Sanofi Bolsters Immunology Pipeline with Acquisition of Dren Bio’s DR-0201 for Up to $1.9 Billion
March 20th 2025DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing promise in treating refractory B-cell-mediated autoimmune diseases.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Phase III Trials Show Povorcitinib Significantly Improves Hidradenitis Suppurativa Outcomes
March 19th 2025In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory nodule count.